Ovascience Company

Founded in 2011 by Michelle Dipp, Richard Aldrich, Christoph Westphal, Jonathan Tilly, and David Sinclair based on scientific work done by Tilly concerning mammalian oogonial stem cells and work on mitochondria by Sinclair. Tilly's work was controversial, with some groups unable to replicate it. It has also the subject of open scrutiny by MIT Technology Review and New Scientist.In 2016 Overscience was developing two in vitro fertilization services. One, which it called "Augment", it would harvest putative oogonial stem cells from a woman, extract mitochondria from those cells, and inject them into an oocyte from the woman, along with sperm, in a form of augmented intracytoplasmic sperm injection ("ICSI"). In the other, which it called "OvaTure," it would harvest putative oogonial stem cells from a woman, mature them into oocytes in vitro, and then fertilize them with ICSI. It had introduced the Augment service in 2014 in ten clinics located in the United Arab Emirates, Canada, and Japan. By September 2016 OvaScience had raised and spent around $228 million. In 2018 it merging with Millendo Therapeutics, which focuses on endocrine diseases.
Technology: Biotechnology, Health Care, Life Science
Industry: Longevity
Headquarters: Boston, Massachusetts, United States
Founded Date: 2011
Employees Number: 51-100
Funding Status: M&A

Visit Website
info@ovascience.com
twitter.com/OvaScience
Register and Claim Ownership